Oncotarget

Research Papers: Immunology:

Ineffectiveness of the 2014-2015 H3N2 influenza vaccine

Michal Mandelboim _, Aharona Glatman-Freedman, Yaron Drori, Hilda Sherbany, Rakefet Pando, Hanna Sefty, Hila Zadka, Tamar Shohat, Nathan Keller and Ella Mendelson

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:1185-1192. https://doi.org/10.18632/oncotarget.6746

Metrics: PDF 1642 views  |   HTML 2449 views  |   ?  


Abstract

Michal Mandelboim1, Aharona Glatman-Freedman2,3, Yaron Drori1, Hilda Sherbany1, Rakefet Pando1, Hanna Sefty2, Hila Zadka2, Tamar Shohat2,4, Nathan Keller5,6 and Ella Mendelson1,4

1 Central Virology Laboratory, Ministry of Health, Chaim Sheba Medical Center, Ramat-Gan, Israel

2 The Israel Center for Disease Control, Israel Ministry of Health, Tel-Hashomer, Israel

3 Departments of Pediatrics and Family and Community Medicine, Valhalla, New York, USA

4 Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

5 Department of Clinical Microbiology, Sheba Medical Center, Tel-Hashomer, Israel

6 Ariel University Centre, Ariel, Israel

Correspondence to:

Michal Mandelboim, email:

Keywords: influenza, vaccine, Immunology and Microbiology Section, Immune response, Immunity

Received: September 17, 2015 Accepted: November 27, 2015 Published: December 23, 2015

Abstract

The seasonal influenza vaccine is currently the most effective preventive modality against influenza infection. Nasopharyngeal samples of vaccinated and non-vaccinated patients presenting with Influenza-like-illness (ILI) were collected from over 20 outpatient clinics located in different geographic parts of Israel and were tested for the presence of influenza viruses (influenza A and influenza B). Here we show, that in the 2014-2015 season, the vaccine that included the A/Texas/50/2012 H3N2 virus was ineffective. Significant numbers of individuals vaccinated with the 2014-2015 vaccine, of all ages, were infected with influenza A (H3N2), manifesting similar symptoms as the non-vaccinated group. We further demonstrate that the Israeli circulating influenza A(H3N2) virus was different than that included in the 2014-2015 northern hemisphere vaccine, and that antibodies elicited by this vaccine were significantly less efficient in neutralizing influenza A(H3N2) infection.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6746